Prediction of Resistant Mutations against Upcoming ALK-TKIs, Repotrectinib (TPX-0005) and Ensartinib (X-396)
Y. Doi, H. Tagaya, A. Noge, K. Semba
The paper predicts resistant mutations against new ALK-TKIs, repotrectinib and ensartinib, using an error-prone PCR-based system, suggesting their potential as second-line treatments after alectinib.
bioRxiv · May 26, 2022 · PreprintCancer Biology